Patent details

Basic Information

Publication number:

EP3504327

PCT Application Number:

US2017048409

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP178444121

PCT Publication Number:

WO2018039448

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

ENGINEERED TARGET SPECIFIC NUCLEASES

French Title of Invention:

NUCLÉASES SPÉCIFIQUES DE CIBLE SPÉCIFIQUEMENT MODIFIÉES

German Title of Invention:

MANIPULIERTE ZIELSPEZIFISCHE NUKLEASEN

SPC Number:

Dates

Filing date:

24/08/2017

Grant date:

06/10/2021

EP Publication Date:

03/07/2019

PCT Publication Date:

01/03/2018

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

06/10/2021

EP B1 Publication Date:

06/10/2021

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

24/08/2022

Expiration date:

24/08/2037

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

29/09/2021

 

 

Name:

Sangamo Therapeutics, Inc.

Address:

7000 Marina Blvd, Brisbane, CA 94005, United States (US)

Inventor

1

Name:

REBAR, Edward J.

Address:

United States (US)

2

Name:

MILLER, Jeffrey C.

Address:

United States (US)

Priority

1

Priority Number:

201662378978 P

Priority Date:

24/08/2016

Priority Country:

United States (US)

2

Priority Number:

201762443981 P

Priority Date:

09/01/2017

Priority Country:

United States (US)

Classification

IPC classification:

C12N 9/22; A61K 38/00;

Publication

European Patent Bulletin

Issue number:

202140

Publication date:

06/10/2021

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages